Skip to main content

Table 1 Demographic information and biomarker data

From: Diagnostic value of cerebrospinal fluid tau, neurofilament, and progranulin in definite frontotemporal lobar degeneration

  

FTLD subgroups

  
    

FTLD-TDP subgroups

  
 

FTLD

FTLD-tau

FTLD-TDP

FTLD-C9orf72

FTLD-GRN

Controls

Alzheimer’s disease

Gender, % male/female (n)

50/50

(46)

70/30

(10)

44/56

(34)

37/63

(19)

56/44

(9)

55/45

(20)

49/51

(45)

Age at LP (years)

63.6

(55.1–71.7)a

70.3

(56.2–74.4)

63.3

(54.5–71.6)

59.0

(53.7–69.5)*

67.3

(63.3–71.9)

69.4

(61.5–74.7)

71.2

(66.7–79.2)

Age at onset (years)

62.0

(53.8–69.2)a

56.0

(54.0–71.0)

63.5

(52.8–69.2)

56.0

(48.0–67.0)

66.0

(61.5–70.0)

N/A

69.5

(64.3–75.8)

Age at death (years)

65.9

(60.2–75.1)

74.0

(60.8–76.2)

62.9

(57.5–72.5)

57.7

(52.3–62.6)*†

69.1

(61.1–74.2)

N/A

N/A

APOE ε4 carriers, % (n)

32.4

(37)

57.1

(7)

27.6

(29)

30.8

(13)

20.0

(10)

33.3

(6)

59.5

(42)

MMSE at LP (0–30), (n)

21 (15–25)

(29)

23 (22–27)

(5)

19 (14–25)

(23)

15 (7–21)

(10)†

23 (16–26)

(7)

N/A

20 (15–25)

(42)

Serum progranulin (ng/mL)

95

(60–126)a,b

96

(76–167)*

95

(61–125)

107

(91–125)*

48

(39–63)

130

(101–175)

119

(98–145)

CSF progranulin (ng/mL)

3.39

(2.29–3.85)a

3.79

(2.94–4.23)*

3.00

(2.10–3.64)

3.21

(2.35–3.74)*

1.93

(0.97–2.43)

3.61

(2.92–4.50)

3.88

(3.22–4.59)

CSF Aβ1–42 (pg/mL)

641

(457–858)a

543

(438–960)

698

(481–862)

695

(457–819)

708

(578–943)

812

(646–1108)

509

(372–594)b

CSF t-tau (pg/mL)

320

(219–420)a

331

(197–400)

330

(236–464)

252

(178–332)*

379

(296–559)

257

(173–381)

627

(429–928)b

CSF p-tau181 (pg/mL)

36.7

(28.3–49.0)a

35.5

(26.9–58.8)

37.2

(28.8–49.0)

33.0

(22.0–49.0)

36.0

(30.9–42.5)

40.3

(32.9–58.6)

80.0

(60.5–105.0)b

CSF p-tau181/t-tau ratio

0.117

(0.097–0.149)b

0.144

(0.095–0.152)*

0.116

(0.092–0.145)

0.142

(0.105–0.164)*

0.088

(0.076–0.114)

0.176

(0.156–0.197)

0.132

(0.104–0.149)b

CSF Nf-L (pg/mL)

3967

(2556–7148)a,b

2508

(1217–6053)*

4323

(3367–7358)

3446

(2611–4049)*

7323

(5432–9097)

1136

(547–3984)

1597

(1281–2781)

CSF pNf-H (ng/mL)

0.43

(0.21–1.25)

0.54

(0.29–1.45)*

0.41

(0.16–0.95)

0.45

(0.22–0.95)*

0.04

(0.04–0.33)

0.33

(0.04–1.36)

0.47

(0.19–1.43)

  1. Values are presented as median (interquartile range) unless otherwise indicated
  2. Gender and MMSE were analyzed with a Chi-squared test
  3. Kruskal-Wallis test with post-hoc Dunn’s correction was used to compare (full) dementia groups and controls
  4. Significant differences (p < 0.05) are indicated: a compared to Alzheimer’s disease; b compared to controls
  5. Pairwise Mann-Whitney U tests were used to compare FTLD subgroups
  6. Significant differences (p < 0.05) are indicated: * compared to FTLD-GRN; † compared to FTLD-tau
  7. Aβ amyloid-beta, CSF cerebrospinal fluid, FTLD frontotemporal lobar degeneration, LP lumbar puncture, Nf-L neurofilament light chain, MMSE Mini-Mental State Examination, N/A not applicable, pNf-H phosphorylated neurofilament heavy chain, p-tau 181 phosphorylated tau, t-tau total tau